535 lung cancer patients studied to see how nivolumab performs after chemo
NCT ID NCT04500535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 535 people in France with advanced non-small cell lung cancer who were given nivolumab after at least one round of chemotherapy. Researchers wanted to see how well the drug worked, how long it kept cancer from getting worse, and what side effects occurred in everyday medical practice. The goal was to gather real-world information, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Paris, 75248, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Breathing tube-free lung surgery tested for patients with fragile lungs
- Can standard cancer treatment wake up the immune system? a study investigates.
- Quitlines may double as lung cancer screening boosters
- A mobile app aims to turn health awareness into action — a trial puts it to the test
- Text messages and chatbots may help catch lung cancer earlier in underserved communities
- Shorter radiation course may reduce side effects for lung cancer patients